Nitrogen heteroaryl compound, preparation method and application thereof

By developing an azalyl compound, the problem of the single structure of existing EED inhibitors was solved, effective inhibition of EED protein and PRC2 protein complexes was achieved, and histone H3K27 methylation and cancer cell proliferation was significantly inhibited. New solutions to treat resistance to EZH2 enzyme inhibitors.

CN115703799BActive Publication Date: 2024-11-08SHANGHAI AOLU BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210962092.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-08-11
Filing Date
2022-08-11
Publication Date
2024-11-08
Estimated Expiration
2042-08-11

AI Technical Summary

Technical Problem

The existing EED inhibitor has a single structure, which is difficult to effectively overcome the drug resistance problem of EZH2 enzyme function, and lacks synergistic effects.

Method used

A azaaryl compound was developed to inhibit its activity by binding to EED protein and/or PRC2 protein complexes, with better metabolic stability and anti-cell proliferation activity.

Benefits of technology

Significantly inhibiting the methylation level of histone H3K27 and inhibiting cancer cell proliferation provide a new EED inhibitor strategy that can play a role in the emergence of EZH2 enzyme inhibitor resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115703799B_ABST
    Figure CN115703799B_ABST
Patent Text Reader

Abstract

The present invention discloses an azaaryl compound, a preparation method and application thereof. Specifically, the present invention provides an azaaryl compound as shown in Formula I, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, and also provides a preparation method of the compound, a composition containing the compound, and a use of the compound for preparing a drug for treating diseases or disorders related to the mechanism of action of EED protein and / or PRC2 protein complex. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a nitrogen heteroaryl compound, a preparation method and application thereof. Background Art

[0002] PcG (Polycomb Group) proteins are an important class of chromatin modifying enzymes. They regulate gene transcription by modifying chromatin, thus playing an important role in the growth, differentiation and long-term cell memory of stem cells. In mammalian cells, PcG proteins are mainly divided into two types of transcriptional repressive complexes, namely PRC1 (Polycomb Repressive Complex 1) and PRC2 (Polycomb Repressive Complex 2). Among them, PRC2 inhibits the expression of related genes by methylating lysine 27 (H3K27) of histone 3 in chromatin. The PRC2 protein complex is mainly composed of core proteins such as EZH2 (Enhancer of Zeste Homolog 2) (or its very similar homologous protein EZH1), EED (Embryonicectoderm Development) and SUZ12 (Suppressor of Zeste 12). Among them, EZH2 has enzymatic activity, and can transfer the methyl group of the substrate SAM (S-adenosyl-L-methionine) to H3K27 through the SET (Su(var), E(Z), and Trithorax) protein domain, thereby achieving mono- to tri-methylation modification of H3K27. The enzymatic activity of EZH2 also depends on other components of PRC2, such as the EED protein belonging to the WD40 repeat protein family. The binding of EED to tri-methylated H3K27Me3 has a great allosteric effect on the enzymatic function of EZH2, and on the other hand, it can also locate the PCR2 complex on the chromatin that needs to be modified. Abnormal function of PRC2, such as overexpression or gain-of-function mutation of EZH2, is clinically associated with many tumor diseases, including lung cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, pancreatic cancer, sarcoma, and lymphoma. PRC2 is also associated with a variety of cellular immune functions. For example, EZH2 participates in regulating lymphocyte activation, and can also promote T cell response to tumor cells together with glycolysis. Therefore, developing small molecule inhibitors of PRC2 has important and broad drug development value.

[0003] The research and development of PRC2 inhibitors mainly focuses on the development of two strategies: EZH2 inhibitors and EED inhibitors. Currently, the EZH2 inhibitors that have entered clinical trials include EPZ-6438 (Epizyme, clinical phase II), GSK2816126 (GSK, clinical phase I), and CPI-1205 (Constellation, clinical phase I), etc. Although there are multiple EZH2 inhibitors that have entered the clinical research stage, these inhibitors all contain a common 2-pyridone pharmacophore. In addition, secondary mutations have begun to appear in the clinical treatment of existing EZH2 inhibitors. EED inhibitors have an allosteric inhibitory effect on the EZH2 enzyme function and can achieve the same or similar biological functions as EZH2. On the one hand, EED inhibitors have overcome the drug resistance problem of EZH2 very well, and on the other hand, EED inhibitors can be used in combination with EZH2 inhibitors to achieve better synergistic effects. Therefore, the development of new EED inhibitors is of great significance. Summary of the invention

[0004] The technical problem to be solved by the present invention is that the EED inhibitor in the prior art has a single structure. To this end, the present invention provides a nitrogen heteroaryl compound, a preparation method and application thereof. The nitrogen heteroaryl compound of the present invention exhibits good inhibitory activity on tumor cells and has broad prospects for drug development.

[0005] The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof:

[0006]

[0007] Among them, A is independently

[0008] X is N or CR 2 ;

[0009] R 1 , R 2 and R 3 are independently H, halogen, cyano, R 5b Substituted or unsubstituted amino, R 5b -O-、R 5 Substituted or unsubstituted C 1-4 Alkyl, R 5 Substituted or unsubstituted C 3-6 Cycloalkyl, R 5 Substituted or unsubstituted C1-C4 haloalkyl, -C(=O)R 6 、-CO2R 6 、-C(=O)NR 6 R 7 、-SO2R 6or -SO2NR 6 R 7 ; When there are multiple substituents, they are the same or different;

[0010] R 4 are independently H, halogen, cyano, C 1-4 Haloalkyl, -C(=O)NR 4a1 R 4a2 、-S(=O)2R 4b or -C(=O)R 4c ;

[0011] R 4a1 , R 4a2 and R 4b independently H or C 1-4 alkyl;

[0012] R 4c Independently H, C 1-4 Alkyl or -OC 1-4 alkyl;

[0013] R 5 Independently for C 1-4 Alkyl-O-, C 1-4 Alkyl, C 1-4 Haloalkyl, -N(R 5b R 5b ), amino, fluorine, and hydroxyl groups protected by N protecting groups;

[0014] R 5b , R 6 and R 7 Independently H, C 1-4 Alkyl, C 1-4 Haloalkyl;

[0015] “*” indicates that when the carbon atom marked with “*” is a chiral carbon atom, it is in R configuration, S configuration or a mixture thereof.

[0016] In certain preferred embodiments of the present invention, certain groups in the compound represented by formula (I), its pharmaceutically acceptable salt or its stereoisomer are defined as follows, and the unmentioned groups are the same as those described in any scheme of the present application (referred to as "in certain preferred embodiments of the present invention"):

[0017] The compound represented by formula (I) is selected from the following compounds:

[0018]

[0019] In the above compounds, X, R 1 , R 3 and R 4 The definition of is as above.

[0020] In certain preferred embodiments of the present invention:

[0021] for or a mixture thereof.

[0022] In certain preferred embodiments of the present invention:

[0023] When R 1 , R 2 , R 3 and R 4 When independently halogen, the halogen is fluorine, chlorine, bromine or iodine, preferably chlorine.

[0024] In certain preferred embodiments of the present invention:

[0025] When R 1 , R 2 and R 3 Independently for R 5 Substituted or unsubstituted C 1-4 When the C 1-4 The alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0026] In certain preferred embodiments of the present invention:

[0027] When R 1 , R 2 and R 3 Independently for R 5 Substituted or unsubstituted C 3-6 When the cycloalkyl group is 3-6 The cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0028] In certain preferred embodiments of the present invention:

[0029] When R 1 , R 2 and R 3 Independently for R 5 In the case of substituted or unsubstituted C1-C4 haloalkyl, the halogen is fluorine, chlorine, bromine or iodine, preferably fluorine.

[0030] In certain preferred embodiments of the present invention:

[0031] When R 1 , R 2 and R 3 Independently for R 5 In the case of substituted or unsubstituted C1-C4 haloalkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0032] In certain preferred embodiments of the present invention:

[0033] When R 1 , R 2 and R 3 Independently for R 5 In the case of substituted or unsubstituted C1-C4 haloalkyl, the number of the halogenated groups is 1, 2, 3, 4 or 5; for example, 3.

[0034] In certain preferred embodiments of the present invention:

[0035] When R 1 , R 2 and R 3 Independently for R 5 In the case of a substituted or unsubstituted C1-C4 haloalkyl group, the C1-C4 haloalkyl group is a trifluoromethyl group.

[0036] In certain preferred embodiments of the present invention:

[0037] When R 4 , R 5 , R 5b , R 6 and R 7 When they are independently C1-C4 haloalkyl, the halo is fluorine, chlorine, bromine or iodine, preferably fluorine.

[0038] In certain preferred embodiments of the present invention:

[0039] When R 4 , R 5 , R 5b , R 6 and R 7 When they are independently C1-C4 haloalkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0040] In certain preferred embodiments of the present invention:

[0041] When R 5 When they are independently C1-C4 haloalkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0042] In certain preferred embodiments of the present invention:

[0043] When R 4 , R 5b , R 6 and R 7When they are independently C1-C4 haloalkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0044] In certain preferred embodiments of the present invention:

[0045] When R 4 , R 5 , R 5b , R 6 and R 7 When they are independently C1-C4 haloalkyl, the number of the halogenated groups is 1, 2, 3, 4 or 5; for example, 3.

[0046] In certain preferred embodiments of the present invention:

[0047] When R 4 , R 5 , R 5b , R 6 and R 7 When independently C1-C4 haloalkyl, the C1-C4 haloalkyl is trifluoromethyl.

[0048] In certain preferred embodiments of the present invention:

[0049] When R 4a1 , R 4a2 , R 4b , R 5b , R 6 and R 7 Independently for C 1-4 When it is an alkyl group, the C1-C4 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0050] In certain preferred embodiments of the present invention:

[0051] When R 4c Independently for C 1-4 Alkyl or -OC 1-4 When it is an alkyl group, the C1-C4 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl or ethyl.

[0052] In certain preferred embodiments of the present invention:

[0053] When R 5 Independently for C 1-4 Alkyl, C 1-4 Alkyl-O-, C 1-4 When alkyl halide, the C 1-4 Alkyl, C 1-4 Alkyl-O- and C 1-4C in haloalkyl 1-4 The alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, preferably methyl.

[0054] In certain preferred embodiments of the present invention:

[0055] When R 5 When the amino group is independently protected by an N-protecting group, the protecting group may be R 5a C 1-4 Alkyl or C 1-4 Alkyl-O-; C 1-4 Alkyl and C 1-4 C in alkyl-O- 1-4 The alkyl group may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl;

[0056] For example It may be tert-butyloxycarbonyl.

[0057] In certain preferred embodiments of the present invention:

[0058] X is N.

[0059] In certain preferred embodiments of the present invention:

[0060] R 1 is selected from methyl, cyano, trifluoromethyl, difluoromethyl,

[0061] In certain preferred embodiments of the present invention:

[0062] R 2 For H.

[0063] In certain preferred embodiments of the present invention:

[0064] R 3 is selected from H, methyl, halogen or cyano.

[0065] In certain preferred embodiments of the present invention:

[0066] R 4 Selected from cyano, -C(=O)NR 4a1 R 4a2 、-S(=O)2R 4b or -C(=O)R 4c .

[0067] In certain preferred embodiments of the present invention:

[0068] R 4a1 , R 4a2 , R 4b , R4c , R 5b , R 6 and R 7 are independently methyl.

[0069] In certain preferred embodiments of the present invention:

[0070] X is N;

[0071] R 1 is selected from methyl, cyano, trifluoromethyl, difluoromethyl,

[0072] R 3 is selected from H, methyl, halogen or cyano;

[0073] R 4 Selected from cyano, -C(=O)NR 4a1 R 4a2 、-S(=O)2R 4b or -C(=O)R 4c ;

[0074] R 4a1 , R 4a2 , R 4b and R 4c The definition of is as above.

[0075] In certain preferred embodiments of the present invention:

[0076] X is N;

[0077] R 1 is cyano, R 5b Substituted or unsubstituted amino, R 5 Substituted or unsubstituted C 1-4 Alkyl; for example, R 5 Substituted or unsubstituted amino, R 5 Substituted or unsubstituted C 1-4 alkyl;

[0078] R 3 H, R 5 Substituted or unsubstituted C 1-4 Alkyl, halogen or cyano; for example H;

[0079] R 5 Independently for C 1-4 Alkyl, -N(R 5b R 5b ), hydroxyl group;

[0080] R 4 Selected from cyano, -C(=O)NR 4a1 R 4a2 、-S(=O)2R4b or -C(=O)R 4c ; For example, R 4 Selected from cyano or -S(=O)2R 4b ; For example, R 4b Independently for C 1-4 alkyl;

[0081] R 5b independently H or C 1-4 alkyl.

[0082] In certain preferred embodiments of the present invention:

[0083] X is N;

[0084] R 1 For R 5 Substituted or unsubstituted C 1-4 alkyl;

[0085] R 3 is H;

[0086] R 5 Independently for C 1-4 Alkyl, -N(R 5b R 5b ), hydroxyl group;

[0087] R 4 Selected from cyano or -S(=O)2R 4b ;

[0088] R 4b Independently for C 1-4 alkyl;

[0089] R 5b independently H or C 1-4 alkyl.

[0090] In certain preferred embodiments of the present invention, the compound represented by formula (I) is selected from the compounds shown below:

[0091]

[0092] In the above compounds, R 1 The definition of is as above.

[0093] In certain preferred embodiments of the present invention, the compound described by formula (I) is selected from the compounds shown below:

[0094]

[0095]

[0096] The present invention also provides a method for preparing the compound as shown in formula (I), which comprises the following steps:

[0097] The halogenated intermediate B0 and the intermediate E0 are subjected to coupling reaction to obtain a compound as shown in formula (I);

[0098]

[0099] Wherein, W represents a halogen (such as Br); R x -B(OH)2 or A.R 1 , R 3 , R 4 , X is defined as above.

[0100] The present invention also provides a method for preparing an intermediate compound B0, which can be any of the following schemes:

[0101] Solution 1 includes the following steps:

[0102] Step (1) Compound SM-5 is subjected to ring closure under the action of a catalyst (e.g. phosphorus oxychloride) to obtain compound SM-6,

[0103] Step (2) Compound SM-6 is reacted with an oxidant (e.g., m-chloroperbenzoic acid) to obtain compound SM-7.

[0104] Step (3) Compound SM-7 reacts with H2N-CH2-A in the presence of a base (such as sodium carbonate) to obtain compound B0;

[0105] Solution 2: as shown in step (2) to step (3) in solution 1;

[0106] Solution 3, as shown in step (3) of Solution 1;

[0107] The reaction equation is as follows:

[0108]

[0109] Among them, W, A, R 4 The definition of is as above.

[0110] The solvent involved in the present invention can be selected from: methanol, ethanol, isopropanol, toluene, xylene, chlorobenzene, water, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, dioxane, DMF, acetonitrile, DMSO, NMP, THF or a combination thereof; for example, selected from dichloromethane, chloroform, 1,2-dichloroethane, dioxane, DMF, acetonitrile, DMSO, NMP, THF or a combination thereof.

[0111] The base involved in the present invention may include organic bases and inorganic bases.

[0112] The organic base involved in the present invention can be selected from, for example, TEA, DIPEA or a combination thereof.

[0113] The inorganic base involved in the present invention can be selected from: sodium hydride, sodium methoxide, potassium carbonate, sodium carbonate, cesium carbonate, potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, LiHMDS, LDA, butyl lithium, potassium hydroxide, potassium acetate, lithium aluminum hydride or a combination thereof; for example, selected from sodium hydride, potassium carbonate, sodium carbonate, cesium carbonate, potassium tert-butoxide, sodium tert-butoxide, LiHMDS, LDA, butyl lithium or a combination thereof.

[0114] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the compound as shown in formula (I) as described above, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, and a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may be one or more of a diluent, an absorbent, a wetting agent, a binder, a disintegrant, and a lubricant.

[0115] The present invention also provides the use of the compound represented by formula (I) as described above, its pharmaceutically acceptable salt or stereoisomer, or the pharmaceutical composition as described above in the preparation of a drug. The drug is preferably a drug for treating cancer.

[0116] The present invention also provides the use of the compound represented by formula (I) as described above, its pharmaceutically acceptable salt or stereoisomer thereof, or the pharmaceutical composition as described above in the preparation of a drug for treating cancer mediated by EED protein and / or PRC2 protein complex.

[0117] Preferably, the cancer includes but is not limited to diffuse large B-cell lymphoma, follicular lymphoma, non-Hodgkinson's lymphoma and other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, liver cancer, prostate cancer, breast cancer, brain tumors including neuroblastoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, kidney cancer, rectal cancer, thyroid cancer, parathyroid tumors, uterine tumors and soft tissue sarcoma, etc.

[0118] Preferably, the compound, its pharmaceutically acceptable salt or its stereoisomer is used in combination with other drugs; more preferably, the other drugs are selected from anticancer drugs, tumor immunotherapy drugs, antiallergic drugs, antiemetic drugs, analgesics or cytoprotective drugs.

[0119] The present invention also provides a pharmaceutical preparation, which comprises the compound shown in formula (I) as described above, its pharmaceutically acceptable salt or stereoisomer, or the pharmaceutical composition as described above. The pharmaceutical preparation is preferably in the form of tablets, capsules (such as sustained release or timed release capsules), pills, powders, particles (such as small particles), elixirs, tinctures, suspensions (such as nanosuspensions, microsuspensions) and spray-dried dispersions, syrups, emulsions, solutions, etc. The preferred administration of the pharmaceutical preparation is oral, sublingual, including subcutaneous injection, intravenous injection, intramuscular injection, intrasternal injection, injection, nasal administration (such as nasal membrane inhalation), local surface (such as creams and ointments) administration, rectal administration (such as suppositories) and the like. The compounds disclosed in the present invention can be taken alone or with an appropriate drug carrier.

[0120] The present invention also provides that the aforementioned pharmaceutical preparation can be formulated into an appropriate drug dosage to facilitate and control the dosage of the drug. The dosage regimen of the compound disclosed in the present invention varies according to specific factors, such as pharmacodynamics and mode of administration, the subject, gender, age, health status and weight of the subject, disease characteristics, other concurrent medication conditions, frequency of medication, liver and kidney function, and desired effects, etc. The compound disclosed in the present invention can be taken in a single dose per day, or the total dose can be taken in multiple doses (e.g., two to four times per day).

[0121] The present invention also provides a method for treating cancer, which comprises administering a therapeutically effective amount of the compound as shown in formula (I) as described above, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a pharmaceutical composition as described above to a patient in need of such treatment. The cancers include but are not limited to lymphomas such as diffuse large B-cell lymphoma, follicular lymphoma, non-Hodgkinson lymphoma, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, liver cancer, prostate cancer, breast cancer, brain tumors including neuroblastoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, kidney cancer, rectal cancer, thyroid cancer, parathyroid tumors, uterine tumors and soft tissue sarcoma, etc.

[0122] The present invention also provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof for use in combination with other drugs, wherein the other drugs are selected from: anticancer drugs, tumor immunity drugs, antiallergic drugs, antiemetic drugs, analgesics and cell protection drugs, etc., and the combination has a better effect.

[0123] In the present invention, the cancer is preferably a cancer mediated by the EED protein and / or PRC2 protein complex.

[0124] The present invention also provides a method for inhibiting the activity of EED protein and / or PRC2 protein complex, which comprises administering to a subject a therapeutically effective amount of the compound as shown in formula (I) as described above, a pharmaceutically acceptable salt or a stereoisomer thereof, or the pharmaceutical composition as described above.

[0125] The present invention also provides a method for blocking the binding of EED to H3K27 (e.g., H3K27me3), which comprises administering to a subject a therapeutically effective amount of a compound as shown in formula (I) as described above, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a pharmaceutical composition as described above.

[0126] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here.

[0127] Terminology

[0128] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0129] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0130] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0131] Group Definition

[0132] Definitions of standard chemical terms can be found in references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4THED." Vols. A (2000) and B (2001), Plenum Press, New York). Unless otherwise stated, conventional methods within the technical scope of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods, are used. Unless specifically defined, the terms used herein in the relevant descriptions of analytical chemistry, organic synthetic chemistry, and drugs and medicinal chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and in the treatment of patients. For example, the manufacturer's instructions for the use of the kit can be used, or the reaction and purification can be carried out in a manner known in the art or in accordance with the description of the present invention. The above-mentioned techniques and methods can usually be implemented according to the descriptions in the multiple summary and more specific documents cited and discussed in this specification, according to conventional methods well known in the art. In this specification, groups and substituents thereof can be selected by those skilled in the art to provide stable structural parts and compounds.

[0133] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.

[0134] The section headings used herein are only for the purpose of organizing the article and should not be interpreted as limitations on the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals and papers, are incorporated herein by reference in their entirety.

[0135] Certain chemical groups defined herein are preceded by a shorthand notation to indicate the total number of carbon atoms present in the group. 1-6 Alkyl refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5, 6 carbon atoms). The total number of carbon atoms in the shorthand notation does not include carbons that may be present in substituents of the group.

[0136] When a substituent is listed without indicating the atom through which it is attached to a chemical formula (including but not specifically mentioned compounds), such a substituent may be bonded via any atom thereof. Combinations of substituents and / or their variants are permitted only if such combinations result in stable compounds.

[0137] In addition to the foregoing, when used in the specification and claims of the present application, the following terms have the meanings indicated below unless otherwise specifically stated.

[0138] In various parts of this specification, substituents of compounds disclosed in the present invention are disclosed according to group types or ranges. It is particularly pointed out that the present invention includes each independent subcombination of the individual members of these group types and ranges. The term "C x -C y Alkyl" or "C x-y "Alkyl" refers to a straight or branched chain saturated hydrocarbon containing x to y carbon atoms. For example, the term "C1-C6 alkyl" or "C 1-6 "Alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl disclosed independently; "C 1-4 "C1-C4 alkyl" or "C1-C4 alkyl" specifically refers to methyl, ethyl, C3 alkyl (i.e. propyl, including n-propyl and isopropyl), C4 alkyl (i.e. butyl, including n-butyl, isobutyl, sec-butyl and tert-butyl) disclosed independently.

[0139] When there is no explicit indication that a group has a substituent, such group refers only to unsubstituted groups. For example, when "C1-C4 alkyl" is not preceded by "substituted or unsubstituted", it only refers to "C1-C4 alkyl" itself or "unsubstituted C1-C4 alkyl".

[0140] In various parts of the present invention, linking substituents are described. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood as a linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl", it should be understood that the "alkyl" represents a linked alkylene group.

[0141] In some specific structures, when an alkyl group is clearly indicated as a linking group, the alkyl group represents a linked alkylene group, for example, the C1-C6 alkyl in the group "halo-C1-C6 alkyl" should be understood as a C1-C6 alkylene.

[0142] In addition, it should be noted that, unless otherwise explicitly stated, the description method "... independently are" used in the present invention should be understood in a broad sense, meaning that the individuals described are independent of each other and can independently be the same or different specific groups. In more detail, the description method "... independently are" can mean that in different groups, the specific options expressed by the same symbols do not affect each other; it can also mean that in the same group, the specific options expressed by the same symbols do not affect each other.

[0143] It should be understood that as used herein, the singular forms, such as "a," and "an," include plural references unless otherwise specified.

[0144] The term "one or more" or "one or more than two" means 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.

[0145] In the present application, the term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0146] When it represents a single bond, it means and A mixture of.

[0147] Those skilled in the art will appreciate that, according to the conventions used in the art, the structural formulas used in this application to describe groups and It means that the corresponding group R is connected to other fragments and groups in the compound through this site.

[0148] "Hydroxy" refers to an -OH group.

[0149] "Carbonyl" refers to a -C(=O)- group. When R is a carbonyl group, for

[0150] "Cyano" refers to -CN.

[0151] "Amino" refers to -NH2.

[0152] “R 5b Substituted amino group", R 5b It can be one or two. 5b When there are two, they may be the same group or different groups.

[0153] "Carboxyl" refers to -COOH.

[0154] In the present application, as a group or part of other groups (for example, used in groups such as halogen-substituted alkyl), the term "alkyl" refers to a fully saturated straight or branched hydrocarbon chain group consisting only of carbon atoms and hydrogen atoms, having, for example, 1 to 12 (preferably 1 to 8, more preferably 1 to 6, more preferably 1 to 4) carbon atoms, and connected to the rest of the molecule by a single bond, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, nonyl and decyl.

[0155] In this application, as a group or part of another group, the term "haloalkyl" means that one or more hydrogen atoms in an alkyl group (as defined in the present invention) are replaced by halogens (as defined in the present invention), and the number of halogens can be one or more; when the number of halogens is multiple, the halogens are the same or different. For example, fluoroalkyl means that an alkyl group is replaced by one or more fluorine groups. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, and monofluoromethyl.

[0156] In the present application, preferably, the number of carbon atoms in "heterocycloalkyl" is 3, 4, 5 or 6, the heteroatoms are selected from N, O and S, and the number of heteroatoms is 1, 2, 3 or 4. More preferably, the number of carbon atoms is 4 or 5, the heteroatoms are selected from N and O, and the number of heteroatoms is 1 or 2; for example

[0157] In the present application, preferably, the number of carbon atoms in "heterospirocycloalkyl" is 4, 5 or 6, the heteroatom is selected from N, O and S, the number of heteroatoms is 1, 2, 3 or 4, and more preferably, the heteroatom is selected from N and O, the number of heteroatoms is 1 or 2; for example

[0158] In the present application, as a group or part of other groups, the term "cycloalkyl" means a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting only of carbon atoms and hydrogen atoms, which may include a fused ring system, a bridged ring system or a spiro ring system, having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably 3 to 8 carbon atoms, and which is saturated or unsaturated and can be connected to the rest of the molecule by a single bond via any suitable carbon atom. Unless otherwise specifically indicated in the specification, the carbon atoms in the cycloalkyl group may be optionally oxidized. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, 1H-indenyl, 2,3-dihydroindanyl, 1,2,3,4-tetrahydro-naphthyl, 5,6,7,8-tetrahydro-naphthyl, 8,9-dihydro-7H-benzocyclohepten-6-yl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl, 5,6,7,8,9,10-hexahydro-benzo Cyclooctenyl, fluorenyl, bicyclo[2.2.1]heptyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2]octyl, bicyclo[3.1.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octenyl, bicyclo[3.2.1]octenyl, adamantyl, octahydro-4,7-methylene-1H-indenyl and octahydro-2,5-methylene-pentalenyl, etc.

[0159] In the present application, the term "cycloalkyl" as a group or part of another group means a saturated cyclic hydrocarbon group.

[0160] In the present application, as a group or part of other groups, the term "cycloalkenyl" means a cyclic hydrocarbon group having at least one double bond (such as a carbon-carbon double bond). The cycloalkenyl group can be connected to the rest of the molecule through the double bond atom therein.

[0161] In the present application, as a group or part of other groups, the term "heterocyclyl" means a stable 3- to 20-membered non-aromatic cyclic group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. Unless otherwise specified in this specification, the heterocyclyl can be a monocyclic, bicyclic, tricyclic or more ring system, which can include a fused ring system, a bridged ring system or a spiro ring system; the nitrogen, carbon or sulfur atoms in the heterocyclyl can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl can be partially or fully saturated. The heterocyclyl can be connected to the rest of the molecule via a carbon atom or a heteroatom and by a single bond. In a heterocyclyl containing a fused ring, one or more rings can be an aryl or heteroaryl group as defined below, provided that the point of connection with the rest of the molecule is a non-aromatic ring atom. For the purpose of the present invention, the heterocyclic group is preferably a stable 4- to 11-membered non-aromatic monocyclic, bicyclic, bridged or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, and more preferably a stable 4- to 8-membered non-aromatic monocyclic, bicyclic, bridged or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heterocyclic groups include, but are not limited to, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2,7-diaza-spiro[3.5]nonan-7-yl, 2-oxa-6-aza-spiro[3.3]heptan-6-yl, 2,5-diaza-bicyclo[2.2.1]heptan-2-yl, azetidinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxolane, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, dihydroindolyl, octahydroindolyl, octahydroisoindolyl, pyrrolidinyl, pyrazolidinyl, phthalimido, and the like.

[0162] In the present application, the term "aryl" as a group or part of another group means a conjugated hydrocarbon ring system radical having 6 to 18 carbon atoms, preferably 6 to 10 carbon atoms. For the purposes of the present invention, aryl can be a monocyclic, bicyclic, tricyclic or more ring system, and can also be fused to a cycloalkyl or heterocyclic group as defined above, provided that the aryl is connected to the rest of the molecule by a single bond via an atom on the aromatic ring. Examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, 2,3-dihydro-1H-isoindolyl, 2-benzoxazolinone, 2H-1,4-benzoxazine-3(4H)-one-7-yl, and the like.

[0163] In the present application, the term "arylalkyl" refers to an alkyl group as defined above substituted by an aryl group as defined above.

[0164] In the present application, as a group or part of other groups, the term "heteroaryl" means a 5- to 16-membered conjugated ring system group having 1 to 15 carbon atoms (preferably 1 to 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur in the ring. Unless otherwise specified in this specification, the heteroaryl group can be a monocyclic, bicyclic, tricyclic or more ring system, and can also be fused with a cycloalkyl or heterocyclic group as defined above, provided that the heteroaryl group is connected to the rest of the molecule through a single bond via an atom on the aromatic ring. The nitrogen, carbon or sulfur atoms in the heteroaryl group can be optionally oxidized; the nitrogen atom can be optionally quaternized. For the purpose of the present invention, the heteroaryl group is preferably a stable 5- to 12-membered aromatic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 5- to 10-membered aromatic group containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, or a 5- to 6-membered aromatic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur (for example, the heteroaryl group is a C1-C5 heteroaryl group, wherein the heteroatoms are selected from N, O and S, and the number of heteroatoms is 1, 2, 3 or 4). Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindazolyl, purinyl, quinolyl, isoquinolyl, naphthazinyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, phenanthrolinyl, acridinyl, phenazinyl, isothiazolyl, benzothiazolyl, benzothiophenyl, oxatriol, oxazolyl, cinnolinyl, quinazolinyl, phenylthio, indolizinyl, o-phenanthroline, isoxazolyl, phenoxazinyl, phenothiazinyl, 4,5,6,7-tetrahydrobenzo[b]thienyl, naphthopyridinyl, [1,2,4]triazolo[4,3-b]pyridazine, [1,2,4]triazolo[4,3-a]pyrazine, [1,2,4]triazolo[4,3-c]pyrimidine, [1,2,4]triazolo[4,3-a]pyridine, imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine, imidazo[1,2-a]pyrazine, etc.

[0165] In the present application, "optionally" means that the event or situation described subsequently may or may not occur, and the description includes both the occurrence and non-occurrence of the event or situation. For example, "optionally substituted aryl" means that the aryl is substituted or unsubstituted, and the description includes both substituted aryl and unsubstituted aryl. The "optionally" substituents described in the claims and the specification of the present invention are selected from alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, cyano, nitro, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.

[0166] In the present invention, the term "substituted" or "substituent" means that one or more hydrogen atoms are replaced by a specified group. When the number of substituents is not specified, the substituent can be one or more; when the substitution position is not specified, the substitution can be in any position, but only a stable or chemically feasible chemical is formed.

[0167] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 R, then the group may be optionally substituted with up to two R, and each occurrence of R has independent options. For example, in In the formula (a), when n is 2, it means that the benzene ring is substituted with 2 Rs, and each R has an independent option, that is, the 2 Rs can be the same or different. In addition, the combination of substituents and / or their variants is allowed only if such a combination will produce a stable compound.

[0168] As used herein, the terms "part", "moiety", "chemical moiety", "group", "chemical group" refer to a specific fragment or functional group in a molecule. A chemical moiety is generally considered to be a chemical entity embedded in or attached to a molecule.

[0169] When the compounds of the present invention contain olefinic double bonds, and unless specified otherwise, it is intended that the compounds of the present invention include both E- and Z- geometric isomers.

[0170] "Tautomer" refers to an isomer formed when a proton is shifted from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compounds of the present invention are intended to be encompassed within the scope of the present invention.

[0171] The compounds of the present invention or their pharmaceutically acceptable salts may contain one or more chiral carbon atoms and may therefore produce enantiomers, diastereomers and other stereoisomeric forms. Each chiral carbon atom may be defined as (R)- or (S)- based on stereochemistry. The present invention is intended to include all possible isomers, as well as racemates and optically pure forms thereof. The compounds of the present invention may be prepared using racemates, diastereomers or enantiomers as starting materials or intermediates. Optically active isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as crystallization and chiral chromatography. Stereoisomers of the compounds of the present invention may be (R)- or (S)-isomers.

[0172] Conventional techniques for preparing / isolating individual isomers include chiral synthesis from appropriate optically pure precursors, or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high performance liquid chromatography, see, for example, Gerald Gübitz and Martin G. Schmid (Eds.), Chiral Separations, Methods and Protocols, Methods in Molecular Biology, Vol. 243, 2004; A. M. Stalcup, Chiral Separations, Annu. Rev. Anal. Chem. 3: 341-63, 2010; Fumiss et al. (eds.), VOGEL'S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY 5. sup. TH ED., Longman Scientific and Technical Ltd., Essex, 1991, 809-816; Heller, Acc. Chem. Res. 1990, 23, 128.

[0173] In the present application, the term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0174] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, and the like; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamate, pyroglutamate, aspartate, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbate, salicylates, 4-aminosalicylates, naphthalene disulfonates, and the like. These salts may be prepared by methods known in the art.

[0175] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts. The salt derived from organic base includes but is not limited to the following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the profession.

[0176] In this application, "pharmaceutical composition" refers to a preparation of the compound of the present invention and a medium generally accepted in the art for delivering the biologically active compound to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to promote administration of the organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0177] The term "pharmaceutically acceptable" as used herein refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the compounds of the present invention and is relatively non-toxic, that is, the substance can be administered to a subject without causing adverse biological reactions or interacting in an adverse manner with any components contained in the composition.

[0178] In this application, "pharmaceutically acceptable excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or livestock use.

[0179] As used herein, the terms "prophylactic," "prevention," and "prevention" include reducing the likelihood of a disease or condition occurring or becoming worse in a patient.

[0180] As used herein, the term "treatment" and other similar synonyms include the following meanings:

[0181] (i) preventing a disease or condition from occurring in a mammal, particularly where such mammal is susceptible to the disease or condition but has not yet been diagnosed as having the disease or condition;

[0182] (ii) inhibiting a disease or condition, i.e. arresting its development;

[0183] (iii) alleviate the disease or condition, that is, cause regression of the disease or condition; or

[0184] (iv) alleviating the symptoms caused by the disease or condition.

[0185] As used herein, the term "effective amount", "therapeutically effective amount" or "pharmaceutically effective amount" refers to an amount of at least one agent or compound sufficient to relieve to some extent one or more symptoms of the disease or condition being treated after administration. The result can be a reduction and / or alleviation of signs, symptoms or causes, or any other desired change in a biological system. For example, an "effective amount" for treatment is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant symptom alleviation effect. Techniques such as dose escalation trials can be used to determine the effective amount appropriate for any individual case.

[0186] As used herein, the terms "administering", "administering", "dosing", etc. refer to methods that can deliver a compound or composition to the desired site for biological action. These methods include, but are not limited to, oral routes, intraduodenal routes, parenteral injections (including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. Those skilled in the art are familiar with administration techniques that can be used for the compounds and methods described herein, such as those discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. In preferred embodiments, the compounds and compositions discussed herein are administered orally.

[0187] As used herein, the terms "drug combination", "drug combination", "combination therapy", "administration of other treatments", "administration of other therapeutic agents" and the like refer to drug treatments obtained by mixing or combining more than one active ingredient, including fixed and non-fixed combinations of the active ingredients. The term "fixed combination" refers to the simultaneous administration of at least one compound described herein and at least one synergistic agent to a patient in the form of a single entity or a single dosage form. The term "non-fixed combination" refers to the simultaneous administration of at least one compound described herein and at least one synergistic agent to a patient in the form of separate entities, in combination or sequentially at variable intervals. These also apply to cocktail therapies, for example the administration of three or more active ingredients.

[0188] It will also be appreciated by those skilled in the art that in the methods described below, the functional groups of the intermediate compounds may need to be protected by appropriate protecting groups. Such functional groups include hydroxyl, amino, sulfhydryl and carboxylic acid. Suitable hydroxy protecting groups include trialkylsilyl or diarylalkylsilyl (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, etc. Suitable protecting groups for amino, amidino and guanidino include tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable sulfhydryl protecting groups include -C(O)-R" (wherein R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl, etc. Suitable carboxyl protecting groups include alkyl, aryl or aralkyl esters.

[0189] Protecting groups can be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting groups is described in detail in Greene, TW and PGM Wuts, Protective Groups in OrganiSynthesis, (1999), 4th Ed., Wiley. The protecting group can also be a polymer resin.

[0190] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0191] The reagents and raw materials used in the present invention are commercially available.

[0192] The positive and progressive effect of the present invention is that compared with the compound N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine in US20160176882A1 and WO2017219948A1, the anti-cell proliferation activity of the compound of the present invention is increased by about 10 times. When the compound disclosed in the present invention binds to the EED protein, the bicyclic structure outside the binding "pocket" can make the compound have better metabolic stability. DETAILED DESCRIPTION

[0193] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0194] The starting materials used in the following examples can be purchased from chemical distributors such as Aldrich, TCI, Alfa Aesar, Bidrich, Anergy, etc., or can be synthesized by known methods.

[0195] In the following examples, ice bath refers to -5 degrees Celsius to 0 degrees Celsius, room temperature refers to 10 degrees Celsius to 30 degrees Celsius, and reflux temperature generally refers to the reflux temperature of the solvent under normal pressure. Overnight reaction means a reaction time of 8-15 hours. In the following examples, if the specific operating temperature is not limited, all operations are carried out at room temperature.

[0196] In the following examples, the separation and purification of the intermediates and the final products are carried out by normal or reverse phase chromatographic column separation or other suitable methods. The normal phase flash chromatographic column uses ethyl acetate and n-hexane or methanol and dichloromethane as the mobile phase. The reverse phase preparative high pressure liquid chromatography (HPLC) uses a C18 column and detects with UV 214nm and 254nm, and its mobile phase is A (water and 0.1% formic acid), B (acetonitrile) or mobile phase A (water and 0.1% ammonium bicarbonate), B (acetonitrile).

[0197] In each embodiment:

[0198] LCMS instrument: Pump Agilent 1260 UV Detector: Agilent 1260 DAD

[0199] Mass Spectrometer API 3000

[0200] Chromatography column: Waters sunfire C18, 4.6×50mm, 5μm

[0201] Mobile phase: A-H2O (0.1% HCOOH); B-acetonitrile

[0202] NMR instrument: Bruker Ascend 400M ( 1 H NMR: 400 MHz; 13 C NMR: 100 MHz).

[0203] Example 1 Intermediate 4-(aminomethyl)-5-fluoro-2,3-dihydrobenzofuran-3-ol (A):

[0204] Step 1: Intermediate 2-bromo-3,6-difluorobenzaldehyde (A-2):

[0205]

[0206] A-1 (22 g, 114 mmol) and dry THF (200 mL) were added to a 500 mL dry three-necked flask and cooled to -70 °C. Lithium diisopropylamide (2M, 68.4 mL) was slowly added dropwise to the reaction solution. After the reaction solution was stirred at the same temperature for 45 minutes, DMF (17.8 mL, 228 mmol) was added. The reaction solution was stirred at the same temperature for two hours and then warmed to 0 °C. Saturated ammonium chloride (200 mL) was added to the reaction solution. The reaction solution was extracted with EtOAc (200 mL X 2). The combined organic phase was washed once with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on silica gel (petroleum ether: ethyl acetate = 100: 1) to obtain A-2 (20 g, 79.4% yield) as a light yellow solid.

[0207] 1 H NMR (400MHz, CDCl3) δ10.34(s,1H),7.34(ddd,J=9.2,7.4,4.5Hz,1H),7.16(td,J=9.3,4.0Hz,1H)ppm.

[0208] Step 2: Intermediate 2-bromo-3-fluoro-6-methoxybenzaldehyde (A-3):

[0209]

[0210] A-2 (20 g, 90.5 mmol) was added to a 2L three-necked flask, and dissolved by stirring with anhydrous THF (1000 ml) and MeOH (200 ml). Sodium methoxide (5.87 g, 108.6 mmol) was added, and the reaction solution was stirred at 60°C for 18 hours. Most of the solvent was removed by concentration under reduced pressure, and 500 mL of water was added. The suspension was stirred for 30 minutes and then filtered to collect the solid. The solid was slurried with a mixture of petroleum ether and ethyl acetate (5:1), filtered to obtain a solid, and dried under reduced pressure to obtain A-3 (18 g, 85% yield) as a yellow solid.

[0211] LC-MS: m / z 233.1[M+H] + .

[0212] Step 3: Intermediate 2-bromo-3-fluoro-6-hydroxybenzaldehyde (A-4):

[0213]

[0214] A-3 (16.8 g, 72.1 mmol) and dichloromethane (300 mL) were added to a 1 L single-necked flask. Boron tribromide (21.7 g, 86.5 mmol) was slowly added dropwise at -78 °C, the reaction solution was warmed to room temperature, and stirred for 18 hours. The reaction solution was diluted with dichloromethane (300 mL), and saturated sodium bicarbonate (300 mL) was slowly added. The organic phase was washed twice with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on silica gel (petroleum ether: ethyl acetate = 50: 1) to obtain A-4 (10 g, 63.3% yield) as a light yellow solid.

[0215] 1 H NMR (400MHz, CDCl3) δ11.77(s,1H),10.34(s,1H),7.29(dt,J=12.7,6.3Hz,1H),6.94(dd,J=9.3,4.1Hz,1H)ppm.

[0216] Step 4: Intermediate 4-bromo-5-fluoro-2,3-dihydrobenzofuran-3-ol (A-5):

[0217]

[0218] Trimethylsulfoxide iodide (9.73 g, 44.2 mmol) and DMSO (50 ml) were added to a dry three-necked flask. Sodium tert-butoxide (4.25 g, 44.2 mmol) was added under an ice-water bath. The reaction solution was stirred at room temperature for 2 hours, and A-4 (8.8 g, 40.2 mmol) was added. After the reaction solution was stirred at room temperature for 18 hours, ethyl acetate (250 ml) and water (250 ml) were added, and extracted with ethyl acetate (250 ml x 2). The organic phase was washed once with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on silica gel (petroleum ether: ethyl acetate = 10: 1) to obtain A-5 (6.2 g, 66.2% yield) as a white solid.

[0219] 1 H NMR (400MHz, CDCl3) δ7.03(t,J=8.7Hz,1H),6.76(dd,J=8.8,3.5Hz,1H),5.51-5.40(m,1H),4.58(ddd,J=13.4,10.8,4.6Hz,2H),2.33(d,J=4.9Hz,1H)ppm.

[0220] Step 5: Intermediate 5-fluoro-3-hydroxy-2,3-dihydrobenzofuran-4-carbonitrile (A-6):

[0221]

[0222] A-5 (2.7 g, 11.6 mmol), zinc cyanide (2.04 g, 17.4 mmol), DMF (50 ml) and tetrakistriphenylphosphine palladium (1.34 g, 1.16 mmol) were added to a dry single-necked flask in sequence. The reaction solution was heated to 120 ° C under nitrogen protection and stirred for 18 hours. The reaction solution was cooled to room temperature and extracted with ethyl acetate (200 mL X 3) and water (200 ml). The organic phase was washed once with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on silica gel (petroleum ether: ethyl acetate = 5: 1) to obtain A-6 (1.6 g, 77% yield) as a white solid.

[0223] 1 H NMR (400MHz, CDCl3) δ7.20-6.99(m,2H),5.63(dd,J=6.9,2.9Hz,1H),4.69(dd,J=10.8,7.1Hz,1H),4.55(dd,J=10.8,3.1Hz,1H),2.74(s,1H)ppm.

[0224] Step 6: Intermediate (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine (A2):

[0225]

[0226] A-6 (1.55 g, 8.65 mmol), trifluoroacetic acid (1.09 g, 8.65 mmol), methanol (20 mL) and 10% palladium carbon (2 g, containing 50% water) were added to a 100 mL single-mouth bottle. The reaction mixture was bubbling with hydrogen for 5 minutes, ventilated with a hydrogen balloon three times, and stirred at 60 ° C for 48 hours under a hydrogen balloon. The mixture was filtered through diatomaceous earth, washed with methanol (50 mL x 2), and the filtrate was concentrated under reduced pressure, dioxane (10 mL) and 10M sodium hydroxide aqueous solution (1 mL) were added, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound A2 (1.4 g, 90% purity, 87% yield) was obtained and used directly in the next step.

[0227] 1 H NMR (400MHz, CD3OD) δ3.27(t,2H),3.77(s,2H),4.56(t,2H),6.59(dd 1H),6.81(dd,1H)ppm; LC-MS: m / z 168.1[M+H] + .

[0228] Example 2 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile (BR-1)

[0229] Step 1: 2-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-((diphenylmethylene)amino)acetonitrile (2)

[0230]

[0231] To a solution of sodium hydride (3.63 g, 90.8 mmol, 60% purity) in N,N-dimethylformamide (60.0 mL) at zero degrees, a solution of N-(diphenylmethylene)aminoacetonitrile 1 (10.0 g, 45.4 mmol) in N,N-dimethylformamide (50.0 mL) was added, and 5-bromo-4-chloro-2-(methylthio)pyrimidine (10.8 g, 45.4 mmol) in N,N-dimethylformamide (30.0 mL) was added at zero degrees 2 minutes later, and the mixture was reacted at 40°C for 2 hours. The reaction was monitored by LCMS, and the mixture was quenched with aqueous ammonium chloride solution. The mixture was extracted with ethyl acetate and dried to give a crude product of 2-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-((diphenylmethylene)amino)acetonitrile 2 (15.0 g, crude product), which was used directly in the next step.

[0232] 1 H NMR (400MHz, DMSO-d6) δ7.58-7.52(m,7H),7.44-7.40(m,3H),7.26-7.23(m,2H),4.37(s,3H)ppm; LCMS m / z 424.7[M+H] + .

[0233] Step 2: 2-amino-2-(5-bromo-2-(methylthio)pyrimidin-4-yl)acetonitrile (3)

[0234]

[0235] At zero degrees, 2-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-((benzhydryl)amino)acetonitrile 2 (15.0 g, crude product), tetrahydrofuran (200 mL) and aqueous solution (150 mL) were added with concentrated hydrochloric acid (12 M, 23.6 mL) and reacted at 20°C for 2 hours. The reaction was completed by TLC monitoring, and the reaction solution was vortexed to remove tetrahydrofuran and then sodium hydroxide aqueous solution (1.00 M) was added to adjust the pH to about 8.0, extracted with ethyl acetate, dried, and dried to obtain a crude product 2-amino-2-(5-bromo-2-(methylthio)pyrimidin-4-yl)acetonitrile 3 (9.00 g, crude product) which was directly used in the next step.

[0236] 1 H NMR (400MHz, DMSO-d6) δ8.86(s,1H),5.28(s,1H),2.89(s,2H),2.57(s,3H)ppm; LCMS m / z260.9[M+H] + .

[0237] Step 3: N-((5-bromo-2-(methylthio)pyrimidin-4-yl)(cyano)methyl)formamide (4)

[0238]

[0239] Mix formic acid (39.0 g, 848 mmol) and acetic anhydride (34.8 g, 341 mmol) and react at 50°C for 1 hour. After cooling to 0°C, add to a solution of 2-amino-2-(5-bromo-2-(methylthio)pyrimidin-4-yl)acetonitrile 3 (9.00 g, crude product) in dichloromethane (100 mL). React at 20°C for 2 hours. TLC monitors the completion of the reaction, and the sodium hydroxide aqueous solution (1.00 M) is reduced to 8 at zero degrees. The mixture is extracted with ethyl acetate and dried. The crude product is dried and then column chromatographed to obtain N-((5-bromo-2-(methylthio)pyrimidin-4-yl)(cyano)methyl)formamide 4 (7.00 g, 22.6 mmol, 73.2% yield).

[0240] 1 H NMR (400MHz, DMSO-d6) δ8.86(s,1H),5.28(s,1H),2.89(s,2H),2.57(s,3H)ppm; LCMS m / z260.9[M+H] + .

[0241] Step 4: 8-Bromo-5-(methylthio)imidazo[1,5-c]pyrimidine-1-carbonitrile (5)

[0242]

[0243] Phosphorus oxychloride (28.8 g, 188 mmol) was added to N-((5-bromo-2-(methylthio)pyrimidin-4-yl)(cyano)methyl)formamide 4 (7.00 g, 24.3 mmol) and reacted at 110 degrees for 1 hour. TLC monitored the end of the reaction, selected a portion of the phosphorus oxychloride in the reaction solution, and then quenched with water at <30 degrees, and finally reduced to 8 with NaOH aqueous solution (6.00 M), extracted with ethyl acetate, dried, and the crude product was selected and slurried with petroleum ether / ethyl acetate (5:1, 100 mL), and the solid was filtered out to obtain a pure product. The filtrate was subjected to column chromatography to obtain a small amount of product, and finally combined to obtain 8-bromo-5-(methylthio)imidazo[1,5-c]pyrimidine-1-carbonitrile 5 (3.20 g, 11.7 mmol, 48.1% yield).

[0244] 1 H NMR(400MHz, DMSO-d6)δ8.81(s,1H),8.06(s,1H),2.76(s,3H)ppm; LCMS m / z270.9[M+H] + .

[0245] Step 5: 8-Bromo-5-(methylsulfonyl)imidazo[1,5-c]pyrimidine-1-carbonitrile (6)

[0246]

[0247] 8-Bromo-5-(methylthio)imidazo[1,5-c]pyrimidine-1-carbonitrile 5 (0.60 g, 2.23 mmol) was dissolved in dichloromethane (5 mL), 85% m-chloroperbenzoic acid (1.40 g, 6.91 mmol) was added at 0° C. and stirred at 20° C. for 12 hours. The reaction was completed after LCMS monitoring, and the reaction solution was directly used in the next step.

[0248] LCMS m / z 302.9[M+H] + .

[0249] Step 6: 8-Bromo-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile (7)

[0250]

[0251] 8-Bromo-5-(methylsulfonyl)imidazo[1,5-c]pyrimidine-1-carbonitrile 6 (671 mg, 2.23 mmol) and (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine A (453 mg, 2.23 mmol) were dissolved in dichloromethane (5 mL), sodium carbonate (1.18 g, 11.1 mmol) was added, and the mixture was stirred at 20° C. for 4 hours. The reaction was monitored by LCMS, the reaction solution was diluted with dichloromethane, washed with brine, the organic phase was dried and spin-dried, and then column chromatography was performed to obtain a brown solid product 8-bromo-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile 7 (400 mg, 46.2% yield).

[0252] 1 H NMR (400MHz, DMSO-d6) δ8.90-8.77(m,2H),7.75(s,1H),6.93(t,J=9.4Hz,1H),6.69( dd,J=4.0,8.8Hz,1H),4.67(s,2H),4.53(t,J=8.8Hz,2H),3.29-3.24(m,3H)ppm; LCMS m / z 388.0[M+H] + .

[0253] Step 7: 8-Bromo-5-(bromomethyl)-[1,2,4]triazolo[1,5-a]pyridine (9)

[0254]

[0255] 8-Bromo-5-methyl-[1,2,4]triazolo[1,5-a]pyridine 8 (2g, 9.43mmol) and carbon tetrachloride (20ml) were added to a 100mL round-bottom flask, and NBS (2g, 11.3mmol) and AIBN (310mg, 0.2mmol) were added under an ice-water bath. After the addition was completed, the reaction temperature was raised to 80°C and the reaction was maintained for 16 hours overnight. The reaction solution was washed with an aqueous sodium sulfite solution and then dried to obtain a reddish-brown solid, which was purified by a rapid separation column (eluent: petroleum ether: ethyl acetate = 3:1) to obtain a reddish-brown solid. After vacuum drying, pure 8-bromo-5-(bromomethyl)-[1,2,4]triazolo[1,5-a]pyridine 9 (1.7g, 62% yield) was obtained.

[0256] 1 H NMR (400MHz, CDCl3) δ8.48 (s, 1H), 7.77 (d, J = 7.7Hz, 1H), 7.07 (d, J = 7.7Hz, 1H), 4.90 (s, 2H) ppm; LCMS: m / z 291.9 [M+H] + .

[0257] Step 8: 1-(8-Bromo-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-N,N-dimethylmethanamine (10)

[0258]

[0259] 8-Bromo-5-(bromomethyl)-[1,2,4]triazolo[1,5-a]pyridine 9 (1 g, 3.44 mmol) and tetrahydrofuran (15 ml) were added to a 100 mL round-bottom flask, and 1 M dimethylamine tetrahydrofuran solution (17 ml, 17.2 mmol) and potassium carbonate (0.59 g, 1.43 mmol) were added under an ice-water bath. After the addition was completed, the reaction temperature was raised to 80 ° C and the reaction was maintained for 3 h. After the reaction was completed, the liquid was dried to obtain a yellow-brown solid, which was purified by elution with a rapid separation column (petroleum ether: ethyl acetate = 5:1) to obtain a yellow solid 1-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-N,N-dimethylmethylamine 10 (0.6 g, 68.3% yield).

[0260] 1 H NMR (400MHz, DMSO-d6) δ8.74-8.38(m,1H),8.14-7.85(m,1H),7.31-6.90(m,1H),4.03-3.78(m,2H),2.38-2.20(m,6H)ppm; LCMS: m / z 255.0,257.0[M+H] + .

[0261] Step 9: (5-((Dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)boronic acid (11)

[0262]

[0263] 1-(8-Bromo-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-N,N-dimethylmethanamine 10 (100 mg, 391 μmol), biboronic acid pinacol ester (159 mg, 627 μmol), potassium acetate (115 mg, 1.18 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane (64.0 mg, 78.4 μmol) were dissolved in dioxane (6 mL) in a glove box and reacted at 125° C. for 5 hours. The reaction was completed after LCMS monitoring, and the reaction solution was directly used for the next step reaction.

[0264] LCMS m / z 221.1[M+H] + .

[0265] Step 10: 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile (BR-1)

[0266]

[0267] To the boric acid reaction solution of the previous step were added 8-bromo-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile 7 (151 mg, 390 μmol), potassium carbonate (108 mg, 781 μmol), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane (31.9 mg, 39.0 μmol), water (1 mL), and dioxane (3 mL), and the mixture was reacted at 100°C for 2 hours. The reaction was completed by LCMS monitoring. The reaction solution was concentrated and purified by column chromatography and perp-HPLC. The resulting solution was adjusted to pH 8 with saturated sodium bicarbonate aqueous solution, concentrated to remove the organic solvent, and filtered to give a white solid 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile BR-1 (70.0 mg, 36.8% yield).

[0268] 1H NMR (400MHz, DMSO-d6) δ=8.93(s,1H),8.83(s,1H),8.50(s,1H),7.85-7.76(m,2H),7.32(d,J=7.6Hz,1H),6.96(t,J=9.6Hz ,1H),6.72(dd,J=4.0,8.8Hz,1H),4.77(s,2H),4.56(t,J=8.8Hz,2H),4.03(s,2H),3.35-3.35(m,2H),2.34(s,6H)ppm; LCMS m / z484.4[M+H] + .

[0269] Example 3 5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-8-(5-(2-hydroxypropane-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)imidazo[1,5-c]pyrimidine-1-carbonitrile (BR-2)

[0270] Step 1: (E)-5-bromo-6-(((dimethylamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester E-2

[0271]

[0272] (E)-5-bromo-6-(((dimethylamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester (5.0 g, 21.6 mmol) and 1,1-dimethoxy-N,N-dimethylmethanamine (5.16 g, 43.3 mmol) were dissolved in toluene (100 mL). The reaction solution was heated to 110° C. and reacted for 4 hours. TLC detection showed that no raw material remained. The reaction solution was concentrated to obtain crude (E)-5-bromo-6-(((dimethylamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester E-2 (6.00 g).

[0273] LCMS: m / z 585.7 [M+H] + .

[0274] Step 2: (E)-5-bromo-6-(((hydroxyamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester E-3

[0275]

[0276] (E)-5-bromo-6-(((dimethylamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester E-2 (6.0 g, 20.97 mmol), hydroxylamine hydrochloride (2.91 g, 41.94 mmol), sodium acetate (3.44 g, 41.9 mmol), and ethanol (60 mL) were added to the reaction flask in sequence. The reaction solution was heated to 50°C under a nitrogen atmosphere for 4 hours. The reaction was monitored by LCMS to be complete, and the temperature was cooled to room temperature. (E)-5-bromo-6-(((hydroxylamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester E-3 (5.9 g, 85.0% yield) was obtained by filtration.

[0277] 1 H NMR (400MHz, CDCl3) δ8.27(br d,J=8.5Hz,1H),8.19-8.13(m,1H),7.85(d,J=7.9Hz,1H),7.50(d,J=7.9Hz,1H),3.90(s,3H)ppm; LCMS: m / z 273.7[M+H] + .

[0278] Step 3: 8-Bromo-[1,2,4]triazolo[1,5-a]pyridine-5-carboxylic acid methyl ester E-4

[0279]

[0280] Trifluoroacetic anhydride (23.0 g, 109 mmol) was added dropwise to a solution of (E)-5-bromo-6-(((hydroxylamino)methylene)amino)-pyridine-2-carboxylic acid methyl ester E-3 (10 g, 36.49 mmol) in tetrahydrofuran (100 mL) at room temperature. Then the temperature was slowly raised to 75°C and stirred for 3 hours. After the reaction was completed, a saturated aqueous sodium bicarbonate solution (100 mL) was added to the mixture at 0°C for quenching, and the mixture was extracted with ethyl acetate (100 mL*3). The combined organic phases were dried and concentrated. The concentrate was purified by silica gel column (petroleum ether: ethyl acetate = 5:1 to 4:1) to obtain a white solid product 8-bromo-[1,2,4]triazolo[1,5-a]pyridine-5-carboxylic acid methyl ester E-4 (5.00 g, yield 53.5%).

[0281] Step 4: 2-(8-Bromo-[1,2,4]triazolo[1,5-a]pyridin-5-yl)propan-2-ol E-5

[0282]

[0283] At -30°C, methylmagnesium bromide (3M, 2.60 mL) was added dropwise to a tetrahydrofuran solution (10 mL) of 8-bromo-[1,2,4]triazolo[1,5-a]pyridine-5-carboxylic acid methyl ester E-4 (500 mg, 1.95 mmol) and stirred at this temperature for three hours. After the reaction was completed, water (10 mL) was added to the reaction solution for quenching, and ethyl acetate (10 mL*3) was used for extraction. The combined organic phase was dried, concentrated, and purified by a rapid silica gel column to obtain 2-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-5-yl)propane-2-ol E-5 (400 mg, 80.0% yield).

[0284] 1 H NMR (400MHz, DMSO-d6) δ8.61 (s, 1H), 8.05 (d, J = 8.0Hz, 1H), 7.28 (d, J = 8.0Hz, 1H), 5.91 (s, 1H), 1.72 (s, 6H) ppm; LCMS: m / z 255.9 [M+H] + .

[0285] Step 5: (5-(2-Hydroxypropane-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)boronic acid (12)

[0286]

[0287] 2-(8-Bromo-[1,2,4]triazolo[1,5-a]pyridin-5-yl) tertiary alcohol E-5 (100 mg, 390 μmol), biboronic acid pinacol ester (158 mg, 624 μmol), potassium acetate (114 mg, 1.17 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane (63.7 mg, 78.0 μmol) were dissolved in dioxane (6 mL) in a glove box and reacted at 125° C. for 6 hours. The reaction was completed after LCMS monitoring, and the reaction solution was directly used for the next step reaction.

[0288] LCMS m / z 222.2[M+H] + .

[0289] Step 6: 5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-8-(5-(2-hydroxypropane-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)imidazo[1,5-c]pyrimidine-1-carbonitrile (BR-2)

[0290]

[0291] To the reaction solution of boronic acid 12 in the previous step, 8-bromo-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile 7 (151 mg, 389 μmol), potassium carbonate (107 mg, 778 μmol), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane (31.7 mg, 38.9 μmol), water (1 mL), and dioxane (3 mL) were added, and the mixture was reacted at 100°C for 2 hours. The reaction was completed by LCMS monitoring. The reaction solution was concentrated and purified by column chromatography and perp-HPLC. The resulting solution was adjusted to pH 8 with saturated sodium bicarbonate aqueous solution, concentrated to remove the organic solvent, and filtered to give a white solid 5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-8-(5-(2-hydroxypropane-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)imidazo[1,5-c]pyrimidine-1-carbonitrile (50.0 mg, 26.0% yield).

[0292] 1 H NMR (400MHz, DMSO-d6) δ=8.90(s,1H),8.84(s,1H),8.51(s,1H),7.83-7.78(m,2H),7.44(d,J=7.6Hz,1H),6.95(t,J=9 .4Hz,1H),6.75-6.67(m,1H),5.86(s,1H),4.77(s,2H),4.56(t,J=8.6Hz,2H),3.37-3.32(m,2H),1.77(s,6H)ppm; LCMS m / z 485.4[M+H] + .

[0293] Example 4 8-(5-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile (BR-3)

[0294] Step 1: 8-iodo-N,N-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-5-amine 14

[0295]

[0296] 5-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine 13 (200 mg, 0.72 mmol) was added to a tetrahydrofuran solution of dimethylamine (4 mL, 2M / L). The mixture was stirred at 90 °C for 16 h. LCMS showed that the reaction was complete, and the mixture was concentrated and purified (petroleum ether: ethyl acetate = 1:1) to give 8-iodo-N,N-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-5-amine 14 (190 mg, 90%).

[0297] LCMS: m / z 288.9 [M+H] + .

[0298] Step 2: (5-(Dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)boronic acid (15)

[0299]

[0300] 8-iodo-N,N-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-5-amine 14 (100 mg, 414 μmol), biboronic acid pinacol ester (168 mg, 663 μmol), potassium acetate (122 mg, 1.24 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane (67.7 mg, 82.9 μmol) were dissolved in dioxane (5 mL) in a glove box and reacted at 125° C. for 6 hours. The reaction was completed after LCMS monitoring, and the reaction solution was directly used for the next step reaction.

[0301] LCMS m / z 207.2[M+H] + .

[0302] Step 3: 8-(5-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile

[0303]

[0304] To the reaction solution of boronic acid 15 in the previous step, 8-bromo-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile (160 mg, 412 μmol), potassium carbonate (114 mg, 825 μmol), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane (33.6 mg, 41.2 μmol), water (1 mL), and dioxane (3 mL) were added and the mixture was reacted at 100°C for 2 hours. The reaction was completed by LCMS monitoring. The reaction solution was concentrated and purified by column chromatography and perp-HPLC. The resulting solution was adjusted to pH 8 with saturated sodium bicarbonate aqueous solution, concentrated to remove the organic solvent, and filtered to give a white solid 8-(5-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,5-c]pyrimidine-1-carbonitrile BR-3 (13.0 mg, 6.61% yield).

[0305] 1 H NMR (400MHz, DMSO-d6) δ = 8.90-8.68 (m, 2H), 8.40 (s, 1H), 7.70-7.61 (m, 2H), 6.94 (t, J = 9.2Hz, 1H), 6.74-6.6 6(m,1H),6.56(d,J=8.0Hz,1H),4.74(s,2H),4.55(t,J=8.6Hz,2H),3.37-3.33(m,2H),3.17(s,6H)ppm; LCMS m / z 470.4[M+H] + .

[0306] Example 5 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1-(methylsulfonyl)imidazo[1,5-c]pyrimidin-5-amine (BR-4)

[0307] Step 1: 8-Bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)imidazo[1,5-c]pyrimidin-5-amine (17)

[0308]

[0309] 8-Bromo-5-(methylthio)imidazo[1,5-c]pyrimidine 16 (4.0 g, 16.4 mmol) was dissolved in dichloromethane (60 ml), m-chloroperbenzoic acid (4.99 g, 24.6 mmol, 85% purity) was added at 0°C and reacted at 0°C for 55 minutes, then triethylamine (6.63 g, 65.5 mmol) was added dropwise at 0°C and stirred for 5 minutes, and finally 5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine was added. A (3.34 g, 16.4 mmol, HCl) was added to the reaction solution, the temperature was raised to 20°C and stirred for 3 hours. TLC showed that no raw material remained. Water was added to the reaction solution to quench the mixture, and the mixture was extracted with dichloromethane. The organic phase was washed, dried and concentrated. The crude product was purified by flash silica gel column to obtain 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)imidazo[1,5-c]pyrimidine-5-amine 17 (4.0 g, 40.3% yield).

[0310] 1 H NMR (400MHz, CDCl3) δ8.23(s,1H),7.41-7.30(m,2H),6.87-6.77(m,1H),6.71-6.58(m,1H),6.10(br s,1H),4.79-4.71(m,2H),4.60(t,J=8.8Hz,2H),3.37(t,J=8.8Hz,2H)ppm; LCMS:m / z 363.0[M+H] +

[0311] Step 2: Using the method of Step 10 of Example 2, 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)imidazo[1,5-c]pyrimidin-5-amine (17) and (5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)boric acid (11) as raw materials can be obtained: 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)imidazo[1,5-c]pyrimidin-5-amine (18):

[0312]

[0313] 1H NMR (400MHz, CDCl3) δ8.22(s,1H),8.03(s,1H),7.78(s,1H),7.71(d,J=7.4Hz,1H),7.30-7.27(m,1H),7.07(s,1H),6.87- 6.72(m,1H),6.65(dd,J=3.9,8.6Hz,1H),4.82(s,2H),4.60(t,J=8.8Hz,2H),4.16(s,2H),3.67(t,J=6.0Hz,1H),3.43(br t,J=8.6Hz,2H),2.52(s,6H))ppm; LCMS: m / z 459.2[M+H] +

[0314] Step 3: 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1-iodoimidazo[1,5-c]pyrimidin-5-amine (19)

[0315]

[0316] 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)imidazo[1,5-c]pyrimidin-5-amine (400 mg, 0.782 mmol) was dissolved in acetic acid (2 ml), N-iodosuccinimide (137 mg, 0.62 mmol) was added at 0°C, the temperature was raised to 20°C and the reaction was carried out for 0.25 hours. TL The reaction was completed by monitoring C and LCMS, and the pH of the reaction solution was adjusted to 7, extracted with ethyl acetate, the organic phase was washed, dried and concentrated, and the crude product was purified by flash silica gel column to give 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1-iodoimidazole[1,5-c]pyrimidin-5-amine (190 mg, 33.9% yield).

[0317] 1H NMR(400MHz, DMSO-d6)δ8.73(s,1H),8.53-8.47(m,1H),8.47-8.43(m,1H),7.64(d,J=7.3Hz,1H),7.33-7.26(m, 2H),6.95(t,J=9.4Hz,1H),6.74-6.66(m,1H),4.74(d,J=4.9Hz,2H),4.55(t,J=8.8Hz,2H),4.03(s,2H),3.30(br s,2H),2.35(s,6H)ppm; LCMS:m / z 585.5[M+H] +

[0318] Step 4: 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1-(methylsulfonyl)imidazo[1,5-c]pyrimidin-5-amine (BR-4)

[0319]

[0320] 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1-iodoimidazo[1,5-c]pyrimidin-5-amine (100 mg, 0.172 mmol), cuprous iodide (98 mg, 0.513 mmol), and sodium methanesulfinate (52.4 mg, 0.513 mmol) were dissolved in dimethyl sulfoxide (1 ml) and nitrogen was blown. The reaction mixture was stirred for 5 minutes, microwaved at 120°C for 20 minutes, then reduced to 100°C for 3 hours. The reaction was completed by LCMS monitoring. The reaction solution was concentrated and the crude product was purified by Pre-HPLC to give 8-(5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1-(methylsulfonyl)imidazo[1,5-c]pyrimidin-5-amine (30 mg, 32.3% yield).

[0321] 1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.89-8.80(m,1H),8.36(br s,1H),7.66-7.56(m,2H),7.26-7.15(m,1H),6.96(t,J=9.4Hz,1H),6.75-6.67(m,1H),4.82-4.72(m,2H),4.56(t,J=8.7Hz,2H),3.99(br s,2H),3.31-3.31(m,2H),2.87(s,3H),2.33(br s,6H)ppm; LCMS:m / z 537.2[M+H] +

[0322] Example 6 According to the method of Example 5, (5-(2-hydroxypropane-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)boronic acid (12) was used to replace (5-((dimethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)boronic acid (11) to obtain the following compound:

[0323] 2-(8-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-1-(methylsulfonyl)imidazo[1,5-c]pyrimidin-8-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)propan-2-ol (BR-5) 1 H NMR (400MHz, DMSO-d6) δ8.94(s,1H),8.88-8.76(m,1H),8.38(s,1H),7.65-7.57(m,2H),7.34(d,J=7.4Hz,1H),6.96(t,J=9.4Hz,1H) ,6.80-6.62(m,1H),5.82(s,1H),4.85-4.68(m,2H),4.56(t,J=8.7Hz,2H),3.32-3.31(m,2H),2.88(s,3H),1.76(s,6H)ppm; LCMS:m / z 538.2[M+H] +

[0324]

[0325] Pharmacology and Application

[0326] As one of the main components of the PRC2 protein complex, although EED does not have enzymatic activity, it plays an important role in the overall function of PRC2. The effect of EED on PRC2 is specifically manifested in two aspects: 1) EED directly binds to trimethylated H3K27Me3, so that the PCR2 complex can be positioned on the chromatin that needs to be modified; 2) EED has a great allosteric promoting effect on the enzymatic function of EZH2. Therefore, the development of target compounds for the allosteric protein EED provides a new strategy for inhibiting the activity of EZH2 enzyme. Moreover, such inhibitors have better or complementary advantages than EZH2 enzyme catalytic site inhibitors. For example, when patients develop resistance to EZH2 enzyme inhibitors, EED inhibitors can also inhibit the activity of EZH2 enzyme. The present invention discloses compounds that can be used as EED target inhibitors and have therapeutic effects on diseases related to the mechanism of action of EED and / or PRC2.

[0327] The biological functions of the compounds disclosed in the present invention have been demonstrated in biochemical and cellular tests. For example, in biochemical tests, the compounds disclosed in the present invention can have a strong competitive binding effect (IC 50 At the cellular level, the compounds disclosed in the present invention can not only inhibit the methylation level of histone H3K27 but also inhibit the proliferation of cancer cells through this effect (IC 50 can reach <1nM).

[0328] Example 7: ELISA (H3K27 trimethylation) analysis

[0329] Representative compounds of the present disclosure were diluted 3-fold in DMSO, and 10 concentration gradients were tested for each compound, with the highest concentration being 10 μM. Compounds were diluted 200-fold into G401 cells cultured in 96-well plates (final DMSO concentration was 0.5%). After 72 hours of cell culture, histone H3K27 trimethylation levels were detected by ELISA.

[0330] Histone extraction: The compound-treated cells in a 96-well plate were washed three times with 1x PBS (10x PBS buffer (80 g NaCl (Sigma, product number S3014), 2 g KCl (Sigma, product number 60128), 14.4 g Na2HP04 (Sigma, product number S5136), 2.4 g KH2P04 (Sigma, product number P9791) in 1 L water, pH to 7.4), and 100 μL 0.4N HCl was added to each well and placed at 4°C with gentle shaking for 2 hours to lyse the cells. The cell lysate was then neutralized with 80 μL neutralization buffer (0.5 M disodium hydrogen phosphate, pH 12.5, 2.5 mM DTT; 1% cocktail (Sigma, product number P8340) (mix the cell lysate and neutralization buffer thoroughly).

[0331] ELISA detection method: The cell lysate was transferred to two 384-well detection plates (PerkinElmer, OptiPlate-384HB, product number 6007290) in parallel, one plate was used to detect the level of H3K27 trimethylation, and the other plate was used to determine the level of H3. PBS was adjusted to a final volume of 50 μL / well and coated overnight at 4°C. The next day, the solution in the wells was discarded, and the wells were washed 5 times with TBST buffer (1 xTBS (10x TBS: 24.2g Tris (Sigma, product number T6066), 80g NaCl (Sigma, product number S3014) in 1L water, HCl adjusted to pH 7.6), 0.1% Tween-20), and the water was tapped on absorbent paper. 70 μL of blocking buffer (TBST, 5% BSA) was added to the coated reaction wells and incubated at room temperature for 1 hour. The blocking buffer was discarded and the primary antibody (30 μL / well) was added. All required primary antibodies were diluted with blocking buffer, and the dilution multiples were as follows: anti-H3K27me3 antibody (Cell Signaling Technology, product number 9733), 1:2000 dilution; anti-H3 antibody (Cell Signaling Technology, product number 4499), 1:10000 dilution. After adding the primary antibody, incubate at room temperature for 1 hour. After washing 5 times with TBST, the water was removed, and the secondary antibody (30μL / well) was added to each reaction well and incubated at room temperature for 1 hour. The secondary antibody (anti-rabbit antibody (Jackson ImmunoResearch, product number 111-035-003)) was diluted 2000 times with blocking buffer before use. After 1 hour, wash with TBST and remove the water. Add 30μL of ECL substrate (Pierce, product number 34080) to each well and centrifuge at 2000rpm for 30 seconds. The signal of each sample was detected using Molecular Devices, SpectraMax. Data processing: H3K27 methylation readings were first normalized with H3 signals, and samples treated with 0.5% DMSO were used as controls to calculate the percentage of inhibition of the compounds. The data were fitted to a dose-response curve using the GraphPad prisim5 program to obtain the IC of the test compound. 50 value.

[0332] Table 1 below shows the IC values ​​of some compounds. 50 value.

[0333] Table 1

[0334]

[0335]

[0336] Example 8: Cell proliferation analysis

[0337] Human B cell non-Hodgkin's lymphoma KARPAS-422S cells were cultured in culture flasks using standard cell culture conditions. The culture medium was RPMI-1640 (Invitrogen, product number 11875) containing 15% fetal bovine serum (FBS, Invitrogen, product number 10099-141), 1% penicillin / streptomycin solution (P / S), and the culture flasks were placed in a sterile incubator at 37°C, 95% relative humidity, and 5% CO2. In order to detect the effect of PRC2 inhibitors on cell proliferation, cells in the exponential growth phase were taken and cultured at 1x10 4 The cells / well were inoculated into a 96-well plate (Corning, product number 3904), and 100 μL of culture medium was added to each well. Subsequently, the compounds disclosed in this article at different concentrations were added to the wells inoculated with cells (9 concentration gradients were set for each compound, the highest detection concentration was 10 μM, 3-fold gradient dilution), 2 parallel replicates were set for each treatment concentration, and the final DMSO concentration was 0.5%. After that, the number of viable cells was determined every 3 to 4 days using Vi-CELL (Beckman Coulter). The cells counted each time were incubated at the same density (1X 10 4 Cells / well) were inoculated into a new 96-well plate, fresh medium was added to 100 μL, and different concentrations of compounds were added. On the 13th day of culture, 100 μL of CellTiter-Glo (CellTiter-GloCellTiter-GloCellTiter-GloCTG) (Promega, product number G7573) was added to each well, and placed in the dark at room temperature for 10 to 20 minutes. The luminescence signal was read using Molecular Devices, SpectraMax i3X. GraphPadprisim5 was used to fit the data into a dose-response curve to obtain the IC of the test compound. 50 value.

[0338] Table 5 below shows the IC values ​​of some compounds. 50 value.

[0339] Table 2

[0340]

[0341]

[0342] The compounds disclosed in the present invention can be used to treat cancers related to the mechanism of action of EED protein and / or PRC2 protein complex, including but not limited to diffuse large B-cell lymphoma, follicular lymphoma, non-Hodgkinson's lymphoma, etc. lymphoma, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, liver cancer, prostate cancer, breast cancer, brain tumors including neuroblastoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, kidney cancer, rectal cancer, thyroid cancer, parathyroid tumors, uterine tumors and soft tissue sarcoma, etc.

Claims

1. A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, characterized in that: Among them, A is X is N; R 1 and R 3 are independently H, halogen, cyano, R 5b Substituted or unsubstituted amino, R 5b -O-、R 5 Substituted or unsubstituted C 1-4 Alkyl, or R 5 Substituted or unsubstituted C 1-4 Haloalkyl; when there are multiple substituents, they may be the same or different; R 4 is cyano or -S(=O)2R 4b ; R 4b H or C 1-4 alkyl; R 5 Independently for C 1-4 Alkyl-O-, C 1-4 Alkyl, C 1-4 Haloalkyl, -N(R 5b R 5b ), amino, fluorine, or hydroxyl protected by an N-protecting group, wherein the protecting group is R 5a C 1-4 Alkyl or C 1-4 Alkyl-O-; R 5b Independently H, C 1-4 Alkyl or C 1-4 Halogenated alkyl.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: When R 1 and R 3 When independently halogen, the halogen is fluorine, chlorine, bromine or iodine; and / or, when R 1 and R 3 Independently for R 5 Substituted or unsubstituted C 1-4 When the C 1-4 Alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; and / or, when R 1 and R 3 Independently for R 5 Substituted or unsubstituted C 1-4 When alkyl halide, the C 1-4 The halogen in the haloalkyl group is fluorine, chlorine, bromine or iodine; and / or, when R 1 and R 3 Independently for R 5 Substituted or unsubstituted C 1-4 When alkyl halide, the C 1-4 C in haloalkyl 1-4 Alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; and / or, when R 1 and R 3 Independently for R 5 Substituted or unsubstituted C 1-4 When alkyl halide, the C 1-4 The number of halogen groups in the haloalkyl group is 1, 2, 3, 4 or 5; and / or, when R 5 and R 5b Independently for C 1-4 When alkyl halide, the C 1-4 The halogen in the haloalkyl group is fluorine, chlorine, bromine or iodine; and / or, when R 5 and R 5b Independently for C 1-4 When alkyl halide, the C 1-4 C in haloalkyl 1-4 Alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; and / or, when R 5 and R 5b Independently for C 1-4 When alkyl halide, the C 1-4 The number of halogen groups in the haloalkyl group is 1, 2, 3, 4 or 5; and / or, when R 4b and R 5b C 1-4 When the C 1-4 Alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; and / or, when R 5 Independently for C 1-4 Alkyl, C 1-4 Alkyl-O-, C 1-4 When alkyl halide, the C 1-4 Alkyl, C 1-4 Alkyl-O- and C 1-4 C in haloalkyl 1-4 The alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: When R 5 is independently an amino group protected by an N protecting group, the protecting group being R 5a C 1-4 Alkyl or C 1-4 When alkyl-O-, C 1-4 Alkyl and C 1-4 C in alkyl-O- 1-4 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; and / or, R 1 is selected from methyl, cyano, trifluoromethyl, difluoromethyl, and / or, R 3 is selected from H, methyl, halogen or cyano; and / or, R 4b and R 5b It is methyl.

4. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: The compound described in formula (I) is selected from the following compounds: In the above compounds, R 1 The definition is as shown in claim 1.

5. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: The compound represented by the formula (I) is selected from the following compounds:

6. A method for preparing a compound of formula (I) as claimed in any one of claims 1 to 5, characterized in that: It includes the following steps: The halogenated intermediate B0 and the intermediate E0 are subjected to coupling reaction to obtain a compound as shown in formula (I); Wherein, W represents halogen; R x -B(OH)2 or A.R 1 , R 3 , R 4 , X is defined as in any one of claims 1-5.

7. The preparation method according to claim 6, characterized in that: W is Br.

8. The preparation method according to claim 6, characterized in that: The preparation method of the intermediate B0 is any of the following schemes: Solution 1 includes the following steps: Step (1) Compound SM-5 is subjected to ring closure under the action of a catalyst to obtain compound SM-6, Step (2) Compound SM-6 is reacted with an oxidant to obtain compound SM-7, Step (3) Compound SM-7 reacts with H2N-CH2-A in the presence of a base to obtain compound B0; Solution 2: as shown in step (2) to step (3) in solution 1; Solution 3, as shown in step (3) of Solution 1; The reaction equation is as follows: Among them, W, A, R 4 The definition as set forth in claim 6.

9. A pharmaceutical composition, characterized in that: It comprises a therapeutically effective amount of a compound represented by formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

10. Use of substance A in the preparation of medicine, characterized in that: The substance A is a compound as shown in formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 9; the drug is a drug for treating cancer.

11. The use according to claim 10, characterized in that: The drug is a drug for treating cancer mediated by EED protein and / or PRC2 protein complex.

12. The use according to claim 10 or 11, characterized in that: The cancer is selected from diffuse large B-cell lymphoma, follicular lymphoma, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, liver cancer, prostate cancer, breast cancer, brain tumor, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, kidney cancer, rectal cancer, thyroid cancer, parathyroid tumors, uterine tumors and soft tissue sarcoma.

13. The use according to claim 12, characterized in that: The brain tumor is selected from the group consisting of neuroblastoma, glioma, glioblastoma and astrocytoma.

14. The use according to claim 12, characterized in that: The cancer is selected from diffuse large B-cell lymphoma and follicular lymphoma.

15. A pharmaceutical preparation, characterized in that: It comprises the compound represented by formula (I) or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 5, or the pharmaceutical composition as described in claim 9.

16. The pharmaceutical preparation according to claim 15, characterized in that: The pharmaceutical preparations are tablets, capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups, emulsions and solutions.

17. The pharmaceutical preparation according to claim 15, characterized in that: The administration method of the pharmaceutical preparation is selected from oral, sublingual, subcutaneous, intravenous, intramuscular, intrasternal, nasal, topical and rectal administration; And / or, the pharmaceutical preparation is taken once or multiple times per day.